Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.
Identifieur interne : 001829 ( Ncbi/Curation ); précédent : 001828; suivant : 001830Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.
Auteurs : Kyriakos P. Papadopoulos [France] ; Josep Tabernero ; Ben Markman ; Amita Patnaik ; Anthony W. Tolcher ; José Baselga ; Weiliang Shi ; Coumaran Egile ; Rodrigo Ruiz-Soto ; A Douglas Laird ; Dale Miles ; Patricia M. LorussoSource :
- Clinical cancer research : an official journal of the American Association for Cancer Research [ 1078-0432 ] ; 2014.
Descripteurs français
- KwdFr :
- Administration par voie orale, Adulte, Adulte d'âge moyen, Antinéoplasiques (pharmacologie), Antinéoplasiques (usage thérapeutique), Dose maximale tolérée, Femelle, Humains, Jeune adulte, Mâle, Phosphatidylinositol 3-kinases (antagonistes et inhibiteurs), Quinoxalines (pharmacologie), Quinoxalines (usage thérapeutique), Résultat thérapeutique, Stade de la tumeur, Sujet âgé, Sujet âgé de 80 ans ou plus, Sulfonamides (pharmacologie), Sulfonamides (usage thérapeutique), Surveillance pharmacologique, Sérine-thréonine kinases TOR (antagonistes et inhibiteurs), Transduction du signal (), Tumeurs (anatomopathologie), Tumeurs (métabolisme), Tumeurs (traitement médicamenteux).
- MESH :
- anatomopathologie : Tumeurs.
- antagonistes et inhibiteurs : Phosphatidylinositol 3-kinases, Sérine-thréonine kinases TOR.
- métabolisme : Tumeurs.
- pharmacologie : Antinéoplasiques, Quinoxalines, Sulfonamides.
- traitement médicamenteux : Tumeurs.
- usage thérapeutique : Antinéoplasiques, Quinoxalines, Sulfonamides.
- Administration par voie orale, Adulte, Adulte d'âge moyen, Dose maximale tolérée, Femelle, Humains, Jeune adulte, Mâle, Résultat thérapeutique, Stade de la tumeur, Sujet âgé, Sujet âgé de 80 ans ou plus, Surveillance pharmacologique, Transduction du signal.
English descriptors
- KwdEn :
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antineoplastic Agents (pharmacology), Antineoplastic Agents (therapeutic use), Drug Monitoring, Female, Humans, Male, Maximum Tolerated Dose, Middle Aged, Neoplasm Staging, Neoplasms (drug therapy), Neoplasms (metabolism), Neoplasms (pathology), Phosphatidylinositol 3-Kinases (antagonists & inhibitors), Quinoxalines (pharmacology), Quinoxalines (therapeutic use), Signal Transduction (drug effects), Sulfonamides (pharmacology), Sulfonamides (therapeutic use), TOR Serine-Threonine Kinases (antagonists & inhibitors), Treatment Outcome, Young Adult.
- MESH :
- chemical , antagonists & inhibitors : Phosphatidylinositol 3-Kinases, TOR Serine-Threonine Kinases.
- chemical , pharmacology : Antineoplastic Agents, Quinoxalines, Sulfonamides.
- chemical , therapeutic use : Antineoplastic Agents, Quinoxalines, Sulfonamides.
- drug effects : Signal Transduction.
- drug therapy : Neoplasms.
- metabolism : Neoplasms.
- pathology : Neoplasms.
- Administration, Oral, Adult, Aged, Aged, 80 and over, Drug Monitoring, Female, Humans, Male, Maximum Tolerated Dose, Middle Aged, Neoplasm Staging, Treatment Outcome, Young Adult.
Abstract
This phase I, first-in-human study evaluated the safety, maximum-tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and preliminary efficacy of SAR245409, an inhibitor of pan-Class I phosphoinositide 3-kinase (PI3K) and mTOR, administered orally once or twice daily in patients with advanced solid tumors.
DOI: 10.1158/1078-0432.CCR-13-2403
PubMed: 24583798
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003820
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :003706
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :003706
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :001829
Links to Exploration step
pubmed:24583798Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.</title><author><name sortKey="Papadopoulos, Kyriakos P" sort="Papadopoulos, Kyriakos P" uniqKey="Papadopoulos K" first="Kyriakos P" last="Papadopoulos">Kyriakos P. Papadopoulos</name><affiliation wicri:level="1"><nlm:affiliation>Authors' Affiliations: South Texas Accelerated Research Therapeutics, San Antonio, Texas; Memorial Sloan-Kettering Cancer Center, Memorial Hospital, New York, New York; Sanofi, Cambridge, Massachusetts; Exelixis Inc., South San Francisco, California; Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan; Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain; Monash Institute of Medical Research, Monash University, Melbourne, Victoria, Australia; and Sanofi, Vitry-sur-Seine, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Authors' Affiliations: South Texas Accelerated Research Therapeutics, San Antonio, Texas; Memorial Sloan-Kettering Cancer Center, Memorial Hospital, New York, New York; Sanofi, Cambridge, Massachusetts; Exelixis Inc., South San Francisco, California; Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan; Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain; Monash Institute of Medical Research, Monash University, Melbourne, Victoria, Australia; and Sanofi, Vitry-sur-Seine</wicri:regionArea><wicri:noRegion>Vitry-sur-Seine</wicri:noRegion><wicri:noRegion>Vitry-sur-Seine</wicri:noRegion></affiliation></author><author><name sortKey="Tabernero, Josep" sort="Tabernero, Josep" uniqKey="Tabernero J" first="Josep" last="Tabernero">Josep Tabernero</name></author><author><name sortKey="Markman, Ben" sort="Markman, Ben" uniqKey="Markman B" first="Ben" last="Markman">Ben Markman</name></author><author><name sortKey="Patnaik, Amita" sort="Patnaik, Amita" uniqKey="Patnaik A" first="Amita" last="Patnaik">Amita Patnaik</name></author><author><name sortKey="Tolcher, Anthony W" sort="Tolcher, Anthony W" uniqKey="Tolcher A" first="Anthony W" last="Tolcher">Anthony W. Tolcher</name></author><author><name sortKey="Baselga, Jose" sort="Baselga, Jose" uniqKey="Baselga J" first="José" last="Baselga">José Baselga</name></author><author><name sortKey="Shi, Weiliang" sort="Shi, Weiliang" uniqKey="Shi W" first="Weiliang" last="Shi">Weiliang Shi</name></author><author><name sortKey="Egile, Coumaran" sort="Egile, Coumaran" uniqKey="Egile C" first="Coumaran" last="Egile">Coumaran Egile</name></author><author><name sortKey="Ruiz Soto, Rodrigo" sort="Ruiz Soto, Rodrigo" uniqKey="Ruiz Soto R" first="Rodrigo" last="Ruiz-Soto">Rodrigo Ruiz-Soto</name></author><author><name sortKey="Laird, A Douglas" sort="Laird, A Douglas" uniqKey="Laird A" first="A Douglas" last="Laird">A Douglas Laird</name></author><author><name sortKey="Miles, Dale" sort="Miles, Dale" uniqKey="Miles D" first="Dale" last="Miles">Dale Miles</name></author><author><name sortKey="Lorusso, Patricia M" sort="Lorusso, Patricia M" uniqKey="Lorusso P" first="Patricia M" last="Lorusso">Patricia M. Lorusso</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24583798</idno><idno type="pmid">24583798</idno><idno type="doi">10.1158/1078-0432.CCR-13-2403</idno><idno type="wicri:Area/PubMed/Corpus">003820</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003820</idno><idno type="wicri:Area/PubMed/Curation">003706</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003706</idno><idno type="wicri:Area/PubMed/Checkpoint">003706</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003706</idno><idno type="wicri:Area/Ncbi/Merge">001829</idno><idno type="wicri:Area/Ncbi/Curation">001829</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.</title><author><name sortKey="Papadopoulos, Kyriakos P" sort="Papadopoulos, Kyriakos P" uniqKey="Papadopoulos K" first="Kyriakos P" last="Papadopoulos">Kyriakos P. Papadopoulos</name><affiliation wicri:level="1"><nlm:affiliation>Authors' Affiliations: South Texas Accelerated Research Therapeutics, San Antonio, Texas; Memorial Sloan-Kettering Cancer Center, Memorial Hospital, New York, New York; Sanofi, Cambridge, Massachusetts; Exelixis Inc., South San Francisco, California; Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan; Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain; Monash Institute of Medical Research, Monash University, Melbourne, Victoria, Australia; and Sanofi, Vitry-sur-Seine, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Authors' Affiliations: South Texas Accelerated Research Therapeutics, San Antonio, Texas; Memorial Sloan-Kettering Cancer Center, Memorial Hospital, New York, New York; Sanofi, Cambridge, Massachusetts; Exelixis Inc., South San Francisco, California; Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan; Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain; Monash Institute of Medical Research, Monash University, Melbourne, Victoria, Australia; and Sanofi, Vitry-sur-Seine</wicri:regionArea><wicri:noRegion>Vitry-sur-Seine</wicri:noRegion><wicri:noRegion>Vitry-sur-Seine</wicri:noRegion></affiliation></author><author><name sortKey="Tabernero, Josep" sort="Tabernero, Josep" uniqKey="Tabernero J" first="Josep" last="Tabernero">Josep Tabernero</name></author><author><name sortKey="Markman, Ben" sort="Markman, Ben" uniqKey="Markman B" first="Ben" last="Markman">Ben Markman</name></author><author><name sortKey="Patnaik, Amita" sort="Patnaik, Amita" uniqKey="Patnaik A" first="Amita" last="Patnaik">Amita Patnaik</name></author><author><name sortKey="Tolcher, Anthony W" sort="Tolcher, Anthony W" uniqKey="Tolcher A" first="Anthony W" last="Tolcher">Anthony W. Tolcher</name></author><author><name sortKey="Baselga, Jose" sort="Baselga, Jose" uniqKey="Baselga J" first="José" last="Baselga">José Baselga</name></author><author><name sortKey="Shi, Weiliang" sort="Shi, Weiliang" uniqKey="Shi W" first="Weiliang" last="Shi">Weiliang Shi</name></author><author><name sortKey="Egile, Coumaran" sort="Egile, Coumaran" uniqKey="Egile C" first="Coumaran" last="Egile">Coumaran Egile</name></author><author><name sortKey="Ruiz Soto, Rodrigo" sort="Ruiz Soto, Rodrigo" uniqKey="Ruiz Soto R" first="Rodrigo" last="Ruiz-Soto">Rodrigo Ruiz-Soto</name></author><author><name sortKey="Laird, A Douglas" sort="Laird, A Douglas" uniqKey="Laird A" first="A Douglas" last="Laird">A Douglas Laird</name></author><author><name sortKey="Miles, Dale" sort="Miles, Dale" uniqKey="Miles D" first="Dale" last="Miles">Dale Miles</name></author><author><name sortKey="Lorusso, Patricia M" sort="Lorusso, Patricia M" uniqKey="Lorusso P" first="Patricia M" last="Lorusso">Patricia M. Lorusso</name></author></analytic><series><title level="j">Clinical cancer research : an official journal of the American Association for Cancer Research</title><idno type="ISSN">1078-0432</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Oral</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antineoplastic Agents (pharmacology)</term><term>Antineoplastic Agents (therapeutic use)</term><term>Drug Monitoring</term><term>Female</term><term>Humans</term><term>Male</term><term>Maximum Tolerated Dose</term><term>Middle Aged</term><term>Neoplasm Staging</term><term>Neoplasms (drug therapy)</term><term>Neoplasms (metabolism)</term><term>Neoplasms (pathology)</term><term>Phosphatidylinositol 3-Kinases (antagonists & inhibitors)</term><term>Quinoxalines (pharmacology)</term><term>Quinoxalines (therapeutic use)</term><term>Signal Transduction (drug effects)</term><term>Sulfonamides (pharmacology)</term><term>Sulfonamides (therapeutic use)</term><term>TOR Serine-Threonine Kinases (antagonists & inhibitors)</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Administration par voie orale</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Antinéoplasiques (pharmacologie)</term><term>Antinéoplasiques (usage thérapeutique)</term><term>Dose maximale tolérée</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Phosphatidylinositol 3-kinases (antagonistes et inhibiteurs)</term><term>Quinoxalines (pharmacologie)</term><term>Quinoxalines (usage thérapeutique)</term><term>Résultat thérapeutique</term><term>Stade de la tumeur</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Sulfonamides (pharmacologie)</term><term>Sulfonamides (usage thérapeutique)</term><term>Surveillance pharmacologique</term><term>Sérine-thréonine kinases TOR (antagonistes et inhibiteurs)</term><term>Transduction du signal ()</term><term>Tumeurs (anatomopathologie)</term><term>Tumeurs (métabolisme)</term><term>Tumeurs (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Phosphatidylinositol 3-Kinases</term><term>TOR Serine-Threonine Kinases</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antineoplastic Agents</term><term>Quinoxalines</term><term>Sulfonamides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term><term>Quinoxalines</term><term>Sulfonamides</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Tumeurs</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Phosphatidylinositol 3-kinases</term><term>Sérine-thréonine kinases TOR</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Signal Transduction</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Tumeurs</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antinéoplasiques</term><term>Quinoxalines</term><term>Sulfonamides</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques</term><term>Quinoxalines</term><term>Sulfonamides</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Drug Monitoring</term><term>Female</term><term>Humans</term><term>Male</term><term>Maximum Tolerated Dose</term><term>Middle Aged</term><term>Neoplasm Staging</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Administration par voie orale</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Dose maximale tolérée</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Résultat thérapeutique</term><term>Stade de la tumeur</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Surveillance pharmacologique</term><term>Transduction du signal</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This phase I, first-in-human study evaluated the safety, maximum-tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and preliminary efficacy of SAR245409, an inhibitor of pan-Class I phosphoinositide 3-kinase (PI3K) and mTOR, administered orally once or twice daily in patients with advanced solid tumors.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001829 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 001829 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:24583798
|texte= Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:24583798" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |